Omaveloxolone is a Small molecule drug targeting CDC20 x Nrf2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Risdiplam is a Non-degrading molecular glue targeting SMN2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Nusinersen sodium is a ASO targeting SMN2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Lemborexant is a Small molecule drug targeting Orexin receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

ADO-Trastuzumab Emtansine: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

TARLATAMAB-DLLE is a Bispecific T-cell Engager (BiTE) targeting CD3 x DLL3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Tebentafusp: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Brolucizumab-dbll is a Single-chain FV antibody fragment targeting VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Orelabrutinib is a Small molecule drug targeting BTK, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Selexipag is a Small molecule drug targeting PGI2 receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Pazopanib Hydrochloride is a Small molecule drug targeting FGFR1 x FGFR3 x Flt3L x ITK x LCK x PDGFRα x PDGFRβ x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit, at.

Axitinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.